aiForward is an open, global program created by Aiforia, aiming to advance the use of AI-powered image analysis in medical research, focusing initially on neuroscience, cancer, and lifestyle diseases. The program was launched in December 2018 and has attracted wide international interest — receiving applications from institutes in Norway, the United States, and other countries. These applications are reviewed regularly by an independent Advisory Team, of which the first three internationally-recognized scientific experts have been confirmed.
Advisory Team’s first members are Professor Joseph Geradts from City of Hope
National Medical Center, United States, Dr. Fredric Manfredsson from Michigan
State University, United States, and Dr. Juha Kononen from the Department of
Oncology at Central Finland Hospital. The Advisory Team evaluates the
scientific validity of the proposals and provides expert insights and guidance
on the selected research projects.
three members bring together years of versatile experience from various
positions held at some of the world’s most highly regarded institutes such as
Oxford University and the Dana-Farber Cancer institute, in a wide range of
clinical and molecular research fields from oncology to neuroscience.
Geradts is a board-certified specialist in anatomical pathology and an
accomplished cancer researcher and clinician, recently initiating several
studies that utilize deep learning algorithms for the development of novel
prognostic and predictive breast cancer models. “[Joining the Advisory
Team] allows me to provide my input on research projects that may significantly
advance the application of artificial intelligence in anatomic pathology.
Aiforia has the potential to play a significant role in this area, which I
consider critical to the future of pathology,” Professor Geradts comments
on his new role in reviewing aiForward projects focused on cancer research.
Kononen is also collaborating with Aifoira to provide his advice and expertise
in cancer. Dr. Kononen is a board-certified oncologist and leads the oncology
department at a large hospital in Finland. Meanwhile Dr. Manfredsson, an
assistant professor of Translational Science and Molecular Medicine, will
provide his expertise to neuroscience led projects. He is currently pioneering
research focusing on the engineering and application of viral vectors in the
study and treatment of Parkinson’s disease.
Aiforia is excited to be collaborating with such accomplished
researchers and clinicians in order to launch the first few projects to bring
deep learning AI to the lab bench. AI and deep learning methods hold the
promise of increased consistency and speed in the evaluation of pathologic
specimens, and automated algorithms enable highly quantitative assessments,”
says Professor Geradts, and continues, “They may also allow the identification
and utilization of features in histologic or cytologic specimens that may be
difficult to appreciate or quantify by the human eye and brain.” Aiforia as
well is excited to observe and share the progress of these projects, and the
momentous results that are sure to be generated through the use of AI.
Applications are accepted on a
continuous basis in the fields of cancer, neuroscience, and lifestyle diseases.
These can be submitted through the program website now at www.aiforward.org